Moderna to Provide Business and Pipeline Updates at the 2021 J.P. Morgan Healthcare Conference
04 January 2021 - 11:00PM
Business Wire
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering
messenger RNA (mRNA) therapeutics and vaccines, today announced
that CEO Stéphane Bancel will present an update on the Company and
its pipeline of mRNA development programs at this year’s 39th
annual J.P. Morgan Healthcare Conference.
Mr. Bancel’s presentation will take place virtually on Monday,
January 11th, 2021 at 4:30 p.m. ET. A live webcast will be
available under “Events and Presentations” in the Investors section
of the Moderna website at investors.modernatx.com. A replay of the
webcast will be archived on Moderna’s website for 90 days following
the presentation.
About Moderna
Moderna is advancing messenger RNA (mRNA) science to create a
new class of transformative medicines for patients. mRNA medicines
are designed to direct the body’s cells to produce intracellular,
membrane or secreted proteins that can have a therapeutic or
preventive benefit and have the potential to address a broad
spectrum of diseases. The company’s platform builds on continuous
advances in basic and applied mRNA science, delivery technology and
manufacturing, providing Moderna the capability to pursue in
parallel a robust pipeline of new development candidates. Moderna
is developing therapeutics and vaccines for infectious diseases,
immuno-oncology, rare diseases, cardiovascular diseases, and
autoimmune and inflammatory diseases, independently and with
strategic collaborators.
Headquartered in Cambridge, Mass., Moderna currently has
strategic alliances for development programs with AstraZeneca PLC
and Merck & Co., Inc., as well as the Defense Advanced Research
Projects Agency (DARPA), an agency of the U.S. Department of
Defense, and BARDA. Moderna has been named a top biopharmaceutical
employer by Science for the past six years. To learn more, visit
www.modernatx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210104005146/en/
Investors: Lavina Talukdar Senior Vice President &
Head of Investor Relations 617-209-5834
Lavina.Talukdar@modernatx.com
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Apr 2023 to Apr 2024